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Stage I colorectal carcinoma has excellent prognosis, with 5-year survival rate up to 95%. The occurrence of lymphovascular
invasion, tumor budding, high number of PDC, or lymph node micrometastases is associated with tumor progression. The aim
of this study was to evaluate the mutational status of 62 stage I colorectal carcinomas (CRC) (taken from 37 patients surviving
more than five years since the initial diagnosis and from 25 patients who died of disease) and to correlate it with
histopathological features and the clinical outcome. Mutations of KRAS, NRAS, BRAF, and PIK3CA genes were analyzed
through Myriapod Colon Status Kit, using the high-throughput genotyping platform Sequenom MassARRAY System.
Mutations in those genes were found in 31 cases (50%) and mainly in those with poor prognosis. The most frequent mutations
occurred at codons 12 and 13 of the KRAS gene (40% of cases). We found concomitant PIK3CA mutations in 5 cases (8%). The
presence of PIK3CA mutations was mainly observed in tumors with poor prognosis and with unfavorable histopathological
prognostic features. High PDC grade (P = 0 0112), the presence of tumor budding (P = 0 0334), LVI (P < 0 0001), KRAS
mutations (P = 0 0228), PIK3CA mutations (P = 0 0214), multiple genetic mutations in KRAS and PIK3CA genes (P = 0 039),
and nodal micrometastases (P < 0 0001) were significant prognostic variables for CSS. The presence of LVI was the only
independent and statistically significant prognostic variable for CSS in our cohort of pTNM stage I CRCs. The analysis of
KRAS/PIK3CA mutational status may be used to identify patients with stage I CRC at high risk of bad outcome and who may
need additional treatments, including biological therapies.
1. Introduction
It is well known that pTNM stage I (pT1N0M0 and
pT2N0M0) colorectal carcinoma (CRCs) has an excellent
prognosis, with 5-year survival rate up to 95% [1]. Therefore,
patients with pTNM stage I CRC are not submitted to any
adjuvant treatment after surgery [1]. However, in a small
percentage of cases, they develop recurrences or metastases
during the follow-up, and this event seems to be more
frequent in cases showing lymphovascular invasion (LVI),
tumor budding (TB), a high number of poorly differentiated
clusters (PDC) in the primary tumor, or micrometastases in
regional lymph nodes [2–5].
Up to now, only few studies have investigated the molec-
ular profile of pTNM stage I CRC [6–8]. According to those
studies, the percentage of mutated tumors ranges between
25% and 57%, and mutations mainly involve the KRAS gene
in this subset of CRCs [6–8].
In this study, we aimed to investigate whether there is
any correlation between the molecular profile and clinical
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outcome of pTNM stage I CRCs and whether mutations
in KRAS, BRAF, NRAS, and PIK3CA genes are associated
with histopathological features in this group of tumors.
2. Materials and Methods
2.1. Selection of Cases and Histological Examination. By a
specialized Colorectal Cancer Registry instituted in Modena
in 1984 [9], we identified all patients with stage I CRCs
diagnosed between January 1984 and December 2004 (518
cases) and, among them, we selected those who died of
disease (DOD) during the follow-up (37 cases). Paraffin
blocks of the tumors and the relative haematoxylin and
eosin- (H&E-) stained slides, stored in the archives of the
Pathologic Anatomy of the University of Modena and Reggio
Emilia, were available for only 25 of 32 patients (group A).
This group of patients was matched with a group of 32
patients with stage I CRCs who were alive or who died of
independent diseases (DOID) after a follow-up time longer
than sixty months (group B). Cases in group B were consec-
utive stage I CRCs that fulfilled the inclusion criteria (at least
60-month follow-up) and with available paraffin blocks. All
cases were anonymously collected.
Pathological features, including tumor size (maximum
diameter in centimeters), tumor border configuration
(expanding or infiltrating), WHO histological grade [10],
pTNM stage [11], TB, LVI, grading based on the counting
of PDC [12], and the presence of lymph node micrometas-
tases (MM) [13], were available in all cases.
According to their location, the tumors were divided into
3 groups: (1) tumors located in the right colon, including the
cecum and ascending and transverse colon; (2) tumors
located in the left colon, including descending and sigmoid
colon; and (3) tumors located in the rectum.
In accordance with the pathological staging at diagnosis
(pTNM stage I) and the current oncological guidelines, none
of the patients had been submitted to adjuvant chemoradio-
therapy after surgical resection.
2.2. Molecular Analysis. DNA was extracted from repre-
sentative 10μm-thick sections cut from formalin-fixed
and paraffin-embedded blocks of each tumor sample con-
taining at least 50% tumor cells. Extraction was performed
with QIAamp DNA Mini Kit (Qiagen, Hilden, Germany),
and DNA was quantified with Xpose-NGS (Trinean NV,
Gentbrugge, Belgium). Mutations were detected in genome-
amplified DNA using the high-throughput genotyping
platform Sequenom MassARRAY System (Sequenom, San
Diego, CA, USA) and the Myriapod Colon Status Kit
(Diatech Pharmacogenetics, Italy) following the manufac-
turer’s protocol. This molecular array allows to identify the
most important mutations of KRAS (codons 12, 13, 59, 61,
117, and 146), NRAS (codons 12, 13, 18, 59, 61, 117, and
146), BRAF (codons 594, 600, and 601), and PIK3CA genes
(codons 38, 81, 88, 93, 108, 118, 345, 420, 539, 542, 545,
546, 549, 1021, 1025, 1043, 1047, and 1049). In brief,
25 ng/μ DNA of each specific primitive tumor was amplified
through multiplex PCR, and then unincorporated nucleo-
tides were inactivated by shrimp alkaline phosphatase
(SAP). A single-base extension reaction was performed using
extension primers that hybridize immediately adjacent to
the mutations and a custom mixture of nucleotides. Salts
were removed by the addition of a cation exchange resin.
Multiplexed reactions were spotted into SpectroCHIP II
arrays, and DNA fragments were resolved by MALDI-TOF
on the Compact Mass Spectrometer (Sequenom, San Diego,
CA) with a limit of detection of 5%. Data were evaluated
using MassARRAY Typer Analyser software 4.0, which
allows to identify mutated alleles by comparing the ratio of
the wild-type peak of all suspected mutants and to generate
a specific report.
2.3. Statistical Analysis. Fisher exact and chi-squared tests
were used to assess the statistical association between muta-
tional status of the tumor and the clinicopathological param-
eters. Median age of the patients (68 years) and median size
of the tumors (3 centimeters) were used as cutoff values for
statistical analyses.
Cancer specific survival (CSS) was assessed by the
Kaplan-Meier method, with the date of primary surgery as
the entry date. CSS was characterized as the length of survival
to death from CRC or to the last follow-up date.
The Mantel-Cox log-rank test was applied to assess the
strength of association between CSS and each of the parame-
ters (age and gender of the patient, size of the tumor, WHO
histological grade, PDC grade, pT stage, tumor border
configuration, TB, LVI, and MM) as a single variable.
Subsequently, a stepwise multivariate analysis (Cox
regression model) was utilized to determine the independent
effect of each variable on survival. Multivariate analysis was
carried out by using stepwise method and including only
clinicopathological variables with significant prognostic value
at univariate analyses.
A probability (P) value less than 0.05 was considered
statistically significant. Statistical analysis was done using
MedCalc 12.1.4.0 statistical software (MedCalc Software,
Mariakerke, Belgium).
2.4. Ethical Issues. All procedures were performed in
accordance with the Helsinki Declaration. Ethical issues were
discussed with the Local Ethics Committee. No formal
approval was necessary to perform the histological review
and molecular analyses.
3. Results
Clinical and pathological features of 62 tumors included in
the study are summarized in Table 1. 31 tumors (50%) had
mutations in KRAS, BRAF, and PI3KCA genes; details are
listed in Table 2.
3.1. KRASMutations. 28/62 cases (45%) had mutations in the
KRAS gene. Among those, 22 (78%) had a single KRASmuta-
tion (G13D in 7 cases, G12D in 6 cases, G12V in 5 cases,
G12C in 1 case, G12F in 1 case, A146T in 1, and Q61H in 1),
while 6 showed multiple mutations. In detail, 5 cases had also
PIK3CA mutations (R108H in 2 cases, E545K in 2 cases, and
R88K in 1), and 1 had two additional KRAS mutations
(G12D+G13D+G117N).KRASmutations were significantly
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more frequent in the group of DOD patients (P = 0 019)
(Table 3) Figure 1.
3.2. PIK3CA Mutations. PIK3CA mutations were found in a
total of five cases (Table 2), all of which showed KRASmuta-
tions as well. Mutations were E545K in 2 CRCs, R108K in 2,
and R88Q in 1 (Table 2). The presence of PIK3CAmutations
was significantly more frequent in female patients (P = 0 01)
and in cases with nodal micrometastases (P = 0 017) and
PDC G3 (P = 0 001) (Table 3).
All but one patient with PIK3CA-mutated tumor died of
CRC; the only one who was alive 168 months since the initial
diagnosis had PIK3CA R88Q mutation.
3.3. NRAS Mutations. NRASmutations were not identified in
any of the cases.
3.4. BRAF Mutations. BRAF V600E mutation was found in 3
cases: 2 were from DOD patients, while one was from a
DOID patient, who was alive 167 months since the initial
diagnosis. Due to the limited number of cases with BRAF
mutations, statistical association with other parameters was
not investigated. However, all 3 mutated cases were localized
in the right colon (Table 3).
3.5. CRC with Multiple Mutations.CRCs with multiple muta-
tions (KRAS+PIK3CA or multiple KRAS mutations)
occurred mainly in female patients (P = 0 004) and in DOD
patients (P = 0 006) and had significant association with
lymph node micrometastases (P = 0 011) and high PDC
grade (P = 0 004). Multiple mutations were more frequent
in CRCs showing LVI, though statistical significance was
not reached (Table 3).
3.6. Correlations between CSS and Clinicopathological
Parameters or Mutational Status.Univariate analyses showed
that high PDC grade (P = 0 0112), the presence of tumor
budding (P = 0 0334), LVI (P < 0 0001), KRAS mutations
(P = 0 0228), PIK3CA mutations (P = 0 0214), multiple
genetic mutations in KRAS and PIK3CA genes (P = 0 039)
(Figure 2), and nodal micrometastases (P < 0 0001)
(Figure 2(b)) were significant prognostic variables for CSS
(Table 4). The presence of LVI was the only independent
and statistically significant prognostic variable for CSS in
our cohort of pTNM stage I CRCs (Table 4) (Figure 2(d)).
Table 2: Distribution of KRAS, PIK3CA, and BRAF mutations
according to the status of patients.
Mutations
Patients
alive/DOID
Patients DOD
KRAS G12C 1 0
KRAS G12D 2 4
KRAS G12D+PIK3CA R108H 0 1
KRAS G12D+G13D+G117N 0 1
KRAS G12F 0 1
KRAS G12R+PIKRCA E545K 0 1
KRAS G12V 2 3
KRAS G13D 5 2
KRAS G13D+PIK3CA R88Q 1 0
KRAS G13D+PIK3CA E545K 0 1
KRAS Q61H 1 0
KRAS A146T 0 1
KRAS A 146T+PIK3CA R108H 0 1
BRAF V600E 1 2
Absent (WT) 24 7
DOID: died of independent disease; DOD: died of disease.
Table 1: Clinicopathological characteristics of the 62 CRCs at pTNM stage I.
Clinicopathological variables Total patients (n = 62) Alive/DOID patients (n = 37) DOD patients (n = 25)
M/F 35/27 22/15 13/12
Mean age 69.5 years 68.7 years 70.84 years
Age range 48–90 years 48–85 years 55–90 years
Right colon 11 8 3
Left colon 15 11 4
Rectum 26 18 8
Mean size of the tumor (cms) 3.28 3.23 3.45
Size range of the tumor (cms) 1–6.5 1–5.5 1.5–6.5
pT1/pT2 4/58 1/36 3/22
Micrometastases (present/absent) 17/45 0/37 17/8
Tumor border configuration (expansive/infiltrative) 18/45 14/23 4/21
WHO grading (G1/G2/G3) 9/46/7 3/29/5 6/17/2
PDC grading (G1/G2/G3) 26/23/13 17/14/6 9/9/7
Tumor budding (present/absent) 32/30 15/22 17/8
LVI (present/absent) 22/40 9/28 13/12
DOID: died of independent diseases; DOD: died of disease; M: male; F: female; LVI: lymphovascular invasion.
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4. Discussion
In this study, we investigated the molecular profile of a
cohort of stage I CRCs and assessed its association with
patient’s prognosis and various clinicopathological variables.
While the molecular profile of advanced CRC has been
largely investigated to predict response to biological drugs
[14–16], the mutational status of early CRC (stage I) has been
rarely analyzed [6–8, 17, 18] and only in studies including
stage I CRCs in heterogeneous cohorts of tumors at different
pTNM stages [6–8, 17, 18]. Therefore, to the best of our
knowledge, this represents the first study focused on the
molecular profile of stage I CRC.
Our results can be summarized as follows: (1) mutations
in the genes involved in RAS/MAPK and PI3K-PTEN-AKT
signalling pathways were found in 50% of stage I CRC and
Table 3: Statistical correlations between mutational status and the various clinicopathological parameters of the tumors.
KRAS mutation
P
PIK3CA mutation
P
n mutations/case
P
Absent Present Absent Present 0 1 2
Age
≤68 years 16 15 28 3 16 11 4
>68 years 18 13 0.798 29 2 1 15 14 2 0.588
Gender
Male 24 11 35 0 22 20 0
Female 10 17 0.02 22 5 0.012 9 12 6 0.004
Size
≤3 cms 18 16 31 3 17 14 3
>3 cms 16 12 0.801 26 2 0.652 14 11 3 0.965
Site
Right colon 9 2 11 0 6 5 0
Left colon 9 6 15 0 9 5 1
Rectum 16 20 0.083 31 5 0.14 16 15 5 0.608
pT
T1 1 3 4 0 1 3 0
T2 33 25 0.319 53 5 1 30 22 6 0.329
Nodal micrometastases
Absent 28 17 44 1 27 17 1
Present 6 11 0.086 13 4 0.017 4 8 5 0.001
Tumor border configuration
Expansive 12 6 18 0 11 7 0
Infiltrative 22 22 0.271 39 5 0.309 20 18 6 0.212
WHO grade
G1 4 5 7 2 4 3 2
G2 24 22 43 3 24 18 4
G3 6 1 0.2 7 0 0.202 3 4 0 0.562
PDC grade
G1 23 13 35 1 23 11 2
G2 7 7 14 0 6 8 0
G3 4 8 0.168 8 4 0.001 2 6 4 0.004
Tumor budding
Absent 17 13 27 3 17 10 3
Present 17 15 0.803 30 2 0.666 14 15 3 0.541
LVI
Absent 21 12 32 1 20 12 1
Present 13 16 0.201 25 4 0.176 11 13 5 0.078
Status
Alive, DOID 25 12 36 1 24 12 1
DOD 9 16 0.019 21 4 0.147 7 13 5 0.006
DOID: died of independent diseases; DOD: died of disease; LVI: lymphovascular invasion.
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mainly in cases with poor prognosis rather than in cases with
favourable outcome (72% versus 40%), (2) the most frequent
mutations observed in stage I CRC occurred at codons 12
and 13 of the KRAS gene (G13D, G12D, and G12V muta-
tions), (3) PI3KCA mutations were strongly associated with
KRAS mutations, and (4) synchronous KRAS and PIK3CA
mutations or multiple KRAS mutations at codons 12 and 13
were mainly found in tumors with poor prognosis and with
unfavorable histopathological prognostic features.
Hence, our findings confirm previous evidence that
mutations at codons 12 and 13 (G13D, G12D, and G12V)
of the KRAS gene are the most frequent mutations in stage
I CRC [6–8, 17, 18], while NRAS, BRAF, and PIK3CA muta-
tions are rare in this subgroup of CRC [6–8, 17].
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Figure 1: KRAS and PIK3CA MassArray (Sequenom) graphic assay. pTNM stage I CRCs with unfavourable clinical outcome showed
frequently multiple KRAS mutations involving unusual codons and KRAS mutations associated to PIRKCA mutations.
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The prognostic role of KRAS mutations in stage I CRC
was previously investigated in two studies that showed that
mutations in this gene are associated with shorter overall sur-
vival and recurrence-free survival [6, 18], while the specific
prognostic role of PIK3CA mutations in stage I CRC had
not been analyzed thus far. Our findings showed a significant
association between KRAS or PIK3CAmutations and shorter
CSS. Interestingly, the presence of multiple KRAS mutations
and that of KRAS/PIK3CA bimutations were significant neg-
ative prognostic factors in our patients with stage I CRC. Li
et al. [17] previously demonstrated that KRAS/PIK3CA
bimutations are significantly more frequent in patients with
stage IV CRC, compared to lower-stage carcinomas. KRAS/
PIK3CA bimutations may induce metastasization through
a synergic effect in the activation of PI3K-AKT pathway
[17, 19, 20]. Since KRAS and PIK3CA mutations seem to
be early events in colorectal carcinogenesis [21], we may
hypothesize that early-stage CRCs with bimutations are
more likely to behave as stage IV tumors and to develop dis-
tant metastases and worse outcome during the follow-up.
Besides, in a previous study, we already showed the associa-
tion between KRAS/PIK3CA bimutations and nodal metasta-
ses or lymphovascular invasion [22]. Further supporting the
tendency of bimutated or trimutated stage I CRC to metas-
tasization is that, in our cohort, this subgroup of tumors
had significantly higher frequency of PDC G3 and nodal
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Figure 2: (a–c) Kaplan-Meier curves showing CSS of patients with pTNM stage I CRC according to mutational status of KRAS, BRAF, and
PIK3CA genes. Patients having CRC with (a) KRAS, (b) PIK3CA, or (c) 2 or 3 mutations had significantly lower CSS, compared to patients
with CRC with absent or 1 mutation. (d) Kaplan-Meier curves showing CSS of patients with pTNM stage I CRC according to the presence of
LVI. Patients having CRC with LVI had significantly lower CSS compared to patients with CRC not having LVI.
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Table 4: Univariate and multivariate analyses for CSS in fifty patients with stage I CRC.
Parameter
Univariate analyses Multivariate analyses
HR (95% CI) P HR (95% CI) P
Age
≤68 years 1
>68 years 1.2 (0.5–2.6) 0.642
Gender
Male 1
Female 1.2 (0.5–2.8) 0.537
Size
≤3 cms 1
>3 cms 0.8 (0.4–1.9) 0.783
Site
Right colon 1
Left colon 0.8 (0.2–2.9)
Rectum 1.9 (0.6–5.5) 0.241
pT
T1 1
T2 0.4 (0.07–2.3) 0.139
Nodal micrometastases
Absent 1
Present 10.4 (3.6–29.8) <0.0001
Tumor border configuration
Expansive 1
Infiltrative 2.6 (1.1–6.1) 0.0542
WHO grade
G1 1
G2 0.5 (0.1–1.6)
G3 0.4 (0.08–2.1) 0.322
PDC grade
G1 1
G2 2.6 (1–7.2)
G3 3.6 (1.1–10.9) 0.0112
Tumor budding
Absent 1
Present 2.3 (1–5.2) 0.0334
LVI
Absent 1 1
Present 5.9 (2.6–13.2) <0.0001 6.2 (2.3–16.6) 0.0003
KRAS mutations
Absent 1
Present 2.4 (1.1–5.4) 0.0228
PIK3CA mutations
Absent 1
Present 3.2 (0.5–17.7) 0.0214
Number of mutations/case
0 1
1 2.7 (1.1–6.2)
2/3 5.6 (1.1–27) 0.039
LVI: lymphovascular invasion.
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micrometastases. Indeed, several studies showed that PDC
G3 CRCs have high metastatic potential at any pTNM stage
[23]. In addition, the presence of nodal micrometastases in
bi- or trimutated CRCs indicates disease diffusion in spite
of pTNM stage I. Different from our previous study [24]
on a cohort of CRCs at pTNM stages I, II, III, and IV, the
presence of a single KRAS mutation was not associated with
PDC grade or tumor budding in this group of pTNM stage I
CRCs. Studies on a larger cohort are needed to clarify
whether the association between KRAS mutations and PDC
grade is stage-dependent or not.
Although further studies are necessary to corroborate
these findings, patients with stage I CRC showing this
biomolecular profile—duple or triple mutations—might be
candidate to adjuvant treatments in the aim to prevent unfa-
vorable outcome. The association between KRAS/PIK3CA
multiple mutations and PDC G3 may be used as a screening
tool to select cases with high probability to have KRAS/
PIK3CA bimutations or KRASmultiple mutations and which
may be referred to molecular analyses. Indeed, in order to
avoid costs related to extensive molecular analyses on stage
I CRC, evaluation of KRAS and PIK3CA mutational status
may be limited only to cases showing PDC G3 at histological
examination. Besides, the identification of PIK3CA muta-
tions might also have therapeutic implications. Indeed, there
is some evidence that CRC with PIK3CA mutations could be
treated with PI3K/mTOR inhibitors [25].
Interestingly, the occurrence of LVI emerged as the only
significant and independent prognostic variable in our
patients with stage I CRC, as we already found in a previous
study [26]. Interestingly, two of the pT1 CRCs included in
our cohort who died of disease during the follow-up exhib-
ited multiple synchronous KRAS mutations. Therefore, the
assessment of KRAS/PIK3CA mutational status may be
particularly important to predict prognosis of patients with
pT1 CRC submitted to endoscopic conservative treatments
in the aim to identify patients at high risk of metastatic diffu-
sion and worse outcome, who could be submitted to surgery
and adjuvant treatments.
In conclusion, this is the first study specifically analyzing
the molecular profile of stage I CRC. The presence of KRAS
mutations, that of simultaneous mutations in PIK3CA gene,
or that of multiple KRAS mutations was significantly associ-
ated with shorter CSS. PIK3CA or multiple KRAS mutations
were associated with nodal micrometastases and PDC G3 as
well. If our findings are confirmed in further studies, the
analysis of KRAS/PIK3CA mutational status may be used to
identify patients with stage I or pT1 CRCs at high risk of
worse outcome, who may need additional treatments.
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